<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of &lt;i&gt;Chlamydia trachomatis&lt;/i&gt; infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of <i>Chlamydia trachomatis</i> infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of <i>Chlamydia trachomatis</i> infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine Hsu, MD, MPH, FAAP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Chlamydia trachomatis</em>, a small gram-negative bacterium, is the most common cause of bacterial sexually transmitted infection (STI) in both males and females [<a href="#rid1">1</a>]. In the United States, it is the most commonly reported nationally notifiable disease following SARS-CoV-2 infection (COVID-19). A significant proportion of patients are asymptomatic, thereby providing an ongoing reservoir for infection. The most frequent clinical manifestation of chlamydial infection in males is urethritis, while the most common finding in females is cervicitis.</p><p>The treatment of urethritis, cervicitis, proctitis, and epididymitis secondary to <em>C. trachomatis</em> infection as well as the treatment of asymptomatic infection will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of these diseases, as well as other types of <em>C. trachomatis</em>-related diseases, such as pelvic inflammatory disease (PID), reactive arthritis, lymphogranuloma venereum, and endemic trachoma (an ocular infection seen commonly in the developing world), are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections"</a> and  <a class="medical medical_review" href="/z/d/html/89490.html" rel="external">"Epidemiology of <i>Chlamydia trachomatis</i> infections"</a> and  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Chlamydia and gonorrhea'</a> and  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">"Reactive arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7593.html" rel="external">"Lymphogranuloma venereum"</a> and  <a class="medical medical_review" href="/z/d/html/3026.html" rel="external">"Trachoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3"><span class="h2">Goals of treatment</span><span class="headingEndMark"> — </span>The goals of management are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent complicated infections related to chlamydia and their sequelae (eg, pelvic inflammatory disease [PID], infertility, chronic pelvic pain, ectopic pregnancy, epididymitis). Several trials have suggested that screening and treating young females for <em>C. trachomatis</em> infection reduces the rate of subsequent PID [<a href="#rid2">2-4</a>]; in turn, early therapy of PID, particularly when <em>C. trachomatis</em> is detected, is associated with a reduced risk of ectopic pregnancy and infertility compared with delayed therapy [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decrease the risk of transmission to others; this includes sex partners and infants at delivery, of whom the latter are at risk of acquiring ocular or pulmonary chlamydial infection from an infected mother. (See  <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resolve symptoms; between 83 and 86 percent of symptomatic patients with cervicitis or urethritis improve clinically within two weeks of starting treatment with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevent reinfection; persons with prior chlamydia infection are at high risk for reacquisition. (See <a class="local">'Follow-up testing'</a> below.)</p><p></p><p class="headingAnchor" id="H1538385490"><span class="h2">Indications for empiric therapy</span><span class="headingEndMark"> — </span>Empiric therapy for chlamydial infection should be offered to persons who present with symptoms of cervicitis, PID, urethritis, epididymitis, or acute proctitis. Empiric therapy of these syndromes is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents", section on 'Antibiotic selection'</a> and  <a class="medical medical_review" href="/z/d/html/86698.html" rel="external">"Urethritis in adult males", section on 'Initial therapy'</a> and <a class="local">'Proctitis and rectal infection'</a> below and  <a class="medical medical_review" href="/z/d/html/5460.html" rel="external">"Acute cervicitis", section on 'Empiric therapy'</a>.)</p><p>Patients with a recent known or possible sexual exposure to chlamydia should also be offered empiric therapy. (See <a class="local">'Management of sex partners'</a> below and  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections", section on 'Patients with recent exposure'</a>.)</p><p>In addition, empiric therapy for chlamydia should be given to patients with documented gonococcal infection, unless nucleic acid amplification testing (NAAT) is negative. (See  <a class="medical medical_review" href="/z/d/html/7603.html" rel="external">"Disseminated gonococcal infection", section on 'Treatment of Chlamydia coinfection'</a> and  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Initial treatment of urogenital infection'</a>.)</p><p class="headingAnchor" id="H3549011611"><span class="h2">Antimicrobial susceptibility</span><span class="headingEndMark"> — </span><em>C. trachomatis</em> is uniformly susceptible to tetracyclines and macrolides, and to some but not all fluoroquinolones [<a href="#rid7">7</a>]. Penicillins are associated with in vitro persistence of <em>C. trachomatis</em> [<a href="#rid8">8</a>], although <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> has been effective. Sulfonamides and cephalosporins have limited activity, and the aminoglycosides are inactive. However, for those agents with activity against <em>C. trachomatis</em>, development of antibiotic resistance is exceedingly rare.</p><p>The unique life cycle of <em>C. trachomatis </em>limits the breadth of active agents [<a href="#rid1">1</a>]. The infectious form of the organism, the extracellular elementary body, is metabolically inert and resistant to killing. Thus, antibiotics must target the sequestered intracellular and intravacuolar phases of the life cycle of this pathogen. For this reason, antibiotics with good intracellular penetration must be used. </p><p>In addition, antibiotic concentrations must be present throughout the entire 36- to 48-hour life cycle of the organism. Thus, either a prolonged course of therapy or selection of an antibiotic with a long half-life is required to ensure adequate levels of the antibiotic agent.</p><p>The rarity of emergent antibiotic resistance may be due in part to the intracellular nature of the pathogen, which eliminates the opportunity for rapid evolution of cell surface components that could contribute to drug resistance. Furthermore, the elementary body is relatively inert, which limits opportunities for replication and the generation of antibiotic-resistant mutations. (See <a class="local">'Management of repeat infection'</a> below and  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections"</a>.) </p><p class="headingAnchor" id="H2933838314"><span class="h2">Defining antibiotic efficacy</span><span class="headingEndMark"> — </span>For an antimicrobial regimen to be recommended for treatment of a sexually transmitted infection (STI), the United States Centers for Disease Control and Prevention (CDC) has specifically incorporated the microbiologic eradication as one of four principal outcomes (in addition to symptom resolution, prevention of sequelae, and prevention of transmission) [<a href="#rid9">9</a>]. Microbial cure is a more reliable parameter for drug efficacy than clinical cure for two reasons: (1) a significant proportion of patients may have other coinfections that will not respond to the administered drug; and (2) most patients have no clinical manifestations at baseline.</p><p>However, the accuracy of microbiologic tests used to assess eradication varies. Cell culture is less sensitive than NAAT, and older studies that relied on culture to detect microbiologic treatment failure tended to overestimate cure rates. (See <a class="local">'Doxycycline as preferred agent'</a> below.)</p><p class="headingAnchor" id="H5622559"><span class="h1">COMPREHENSIVE TREATMENT APPROACH</span><span class="headingEndMark"> — </span>Complete care of the patients with <em>C. trachomatis</em> infection includes antibiotic treatment of the infection as well as evaluation and treatment of other sexually transmitted infections (STIs; including gonorrhea and HIV), counseling on adherence and sexual activity, follow-up testing, and management of sex partners. Most infections in females and many in males are asymptomatic and are only found on screening; nevertheless, these should also be treated promptly as outlined below. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Chlamydia and gonorrhea'</a>.)</p><p>Our treatment approach is consistent with recommendations from the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid9">9</a>]. </p><p class="headingAnchor" id="H5623059"><span class="h2">Antibiotic regimens in adults and adolescents</span></p><p class="headingAnchor" id="H5623067"><span class="h3">Doxycycline as preferred agent</span><span class="headingEndMark"> — </span>We agree with CDC recommendations to use <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> as the preferred agent to treat <em>C. trachomatis</em> infection in nonpregnant individuals  (<a class="graphic graphic_table graphicRef141567" href="/z/d/graphic/141567.html" rel="external">table 1</a>) [<a href="#rid9">9</a>]. Doxycycline is given as 100 mg twice daily for seven days; patients should be counseled on the need for adherence for optimal outcome. Delayed-release doxycycline (200 mg daily for seven days) appears as effective as and better tolerated than twice-daily doxycycline but is more costly and may not be available to many patients [<a href="#rid10">10</a>]. Dispensing the drug on site and observing administration of the first dose (directly observed therapy) improve compliance and are recommended when possible [<a href="#rid9">9</a>]. </p><p>Single-dose <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> had previously been another preferred option, but based on mounting evidence that the microbial efficacy of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is superior, especially for rectal infection and possibly pharyngeal infection [<a href="#rid11">11-17</a>], azithromycin is now considered an alternative option. We reserve use of azithromycin for individuals who are unlikely to be able to complete the seven-day doxycycline course (eg, those for whom adherence may be a concern) and administer it as a single, directly observed 1 g dose. Azithromycin is also the preferred option for pregnant individuals. (See <a class="local">'Alternative antibiotics'</a> below and <a class="local">'Pregnant individuals'</a> below.) </p><p>Preference for <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> over <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> is based on the following observations: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Slightly superior microbiologic outcomes overall</strong> – Trials indicate superior microbiologic outcomes, particularly among males; among symptomatic individuals, clinical cure rates are comparable [<a href="#rid15">15</a>]. In a meta-analysis of 23 randomized trials with over 2000 patients that compared the efficacy of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> with that of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> for the treatment of uncomplicated genital <em>C. trachomatis</em> infections in males and females, microbial cure rates were slightly but significantly higher with doxycycline than azithromycin (97.4 versus 96.2 percent, respectively) [<a href="#rid13">13</a>]. A subsequent meta-analysis also reported a higher likelihood of microbiologic cure with doxycycline than with azithromycin, although the difference was only statistically significant among males (relative risk of failure with azithromycin 2.45 [95% CI 1.36-4.41] in males and 1.71 [95% CI 0.48-6.16] in females) [<a href="#rid15">15</a>]. However, earlier studies included in those meta-analyses determined microbiologic cure with culture or enzyme immunoassay testing rather than the more sensitive nucleic acid amplification test (NAAT), so they may not have captured all failures adequately. In one of the trials included in the meta-analyses that randomly assigned males with nongonococcal urethritis to different antibiotic regimens and used NAAT to assess microbiologic cure, a doxycycline-based regimen resulted in a higher clearance rate among 115 males with <em>C. trachomatis</em> infection<em> </em>compared with an azithromycin-based regimen (94.8 versus 77.4 percent, respectively) [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Substantially superior microbiologic outcomes with rectal infection</strong> – Randomized trials of patients with rectal <em>C. trachomatis</em> infection indicate much higher microbiologic cure rates with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> than with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (see <a class="local">'Proctitis and rectal infection'</a> below). Microbial eradication at the rectal site is important for females with urogenital chlamydia, since the majority (approximately 68 percent) of those with <em>C. trachomatis</em> detected on vaginal specimens have concomitant rectal infection [<a href="#rid18">18</a>]; inadequately treated rectal <em>C. trachomatis</em> infection among such individuals may place them at risk for repeat urogenital <em>C. trachomatis</em> infection through autoinoculation from the anorectal site and increase the risk for transmission [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparable adverse effect profile</strong> – Adverse effects are largely similar with the two agents. In comparative studies of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, adverse events occurred in approximately one-quarter of the patients in both treatment arms [<a href="#rid16">16,20</a>]. The most frequently reported adverse events were gastrointestinal in nature and included diarrhea, abdominal pain, nausea and vomiting, and dyspepsia; no serious adverse events were reported.</p><p></p><p>The main advantage of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> is that it can be provided as a single dose on site at the time of diagnosis, thus ensuring adherence and immediate treatment, which are important to reduce the risk of complications, such as pelvic inflammatory disease (PID), with untreated infection. This is particularly important when asymptomatic <em>C. trachomatis</em> infection is detected as part of routine screening, since it is unclear how long the patient may have been infected. In one study of 4158 females with positive screening tests for <em>C. trachomatis</em>, only 24 percent were treated presumptively on the day of their visit [<a href="#rid21">21</a>]. Treatment was ultimately administered in 96 percent of the remaining patients but at a median interval of 21 days. Completion of the multiday <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> schedule is not guaranteed since directly observed therapy for the full course of doxycycline is rarely possible [<a href="#rid22">22</a>]. However, whether seven full days of twice-daily dosing are required for clinical cure is unclear, since microbiologic cures have been attained in patients with suboptimal adherence to a seven-day regimen [<a href="#rid23">23</a>].</p><p>Other antibiotic alternatives are discussed below.</p><p class="headingAnchor" id="H5623088"><span class="h3">Alternative antibiotics</span><span class="headingEndMark"> — </span>The main alternative agents for treatment of <em>C. trachomatis</em> are <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> and <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>  (<a class="graphic graphic_table graphicRef141567" href="/z/d/graphic/141567.html" rel="external">table 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> (1 g orally as a single dose, ideally administered with directly observed therapy) – As discussed above, azithromycin is highly effective against <em>C. trachomatis</em> and offers the potential for directly observed therapy at the time of diagnosis. However, it is considered an alternative because of evidence indicating a lower microbiologic cure rate with azithromycin compared with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. For nonpregnant individuals, we reserve it for patients who are unlikely to be able to complete the full doxycycline course. (See <a class="local">'Doxycycline as preferred agent'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> (500 mg orally once daily for seven days) – We rarely use levofloxacin to treat <em>C. trachomatis</em>. However, if there are other pathogens that should be covered and are expected to be susceptible to quinolones (eg, with epididymitis in males who practice insertive anal sex), it is reasonable to use levofloxacin as an antichlamydial agent. Levofloxacin is highly effective against <em>C. trachomatis</em>. However, it does not offer an advantage over <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and is generally more costly. Fluoroquinolones are also associated with potentially severe adverse effects, so for uncomplicated infections, they are generally reserved for cases when other agents are not appropriate. (See <a class="local">'Epididymitis'</a> below.) </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> and certain other fluoroquinolones previously had a greater role in therapy when they were used to provide coverage for both gonococcal and chlamydial infections, which can coexist. However, because of the emergence of fluoroquinolone drug resistance, they are no longer adequate coverage for <em>Neisseria gonorrhoeae</em>. (See <a class="local">'Evaluate for and treat gonococcal coinfection'</a> below.)</p><p></p><p class="bulletIndent1">Fluoroquinolones are not as well studied for targeted therapy for <em>C. trachomatis</em> as <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>. Several small trials have failed to demonstrate a difference in microbiologic cure rates with various fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a>) versus doxycycline [<a href="#rid15">15,24-26</a>]. However, not all fluoroquinolones are appropriate; specifically, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> results in poor microbiologic outcomes [<a href="#rid27">27</a>]. In contrast, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> has not been studied as targeted therapy for <em>C. trachomatis</em> but has demonstrated good efficacy in treating PID and is recommended as an alternative treatment regimen in select females with PID. (See  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents", section on 'For outpatients who cannot receive cephalosporins'</a>.) </p><p></p><p>Penicillins and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> are notably inferior in their ability to result in microbial cure, with cure rates in the range of 85 to 89 percent [<a href="#rid9">9,28</a>]. Penicillins (ie, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>) are mainly an alternative for pregnant individuals who cannot take other agents. If these options are used for treatment of <em>C. trachomatis</em>, a test of cure is indicated. (See <a class="local">'Test of cure for select patients'</a> below.)</p><p>Sulfonamides and cephalosporins have limited activity and should not be used.</p><p class="headingAnchor" id="H60698042"><span class="h2">Evaluate for and treat gonococcal coinfection</span><span class="headingEndMark"> — </span>Chlamydial and gonococcal infections may coexist in a significant percentage of community patients. All patients with chlamydia should also be tested for gonorrhea. All individuals with a positive NAAT for <em>N. gonorrhoeae</em> warrant treatment for gonorrhea in addition to chlamydia, even if they are asymptomatic. Those who have a negative NAAT for <em>N. gonorrhoeae</em> do not need additional treatment for gonorrhea. Antimicrobial regimens for treatment of gonorrhea are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents"</a>.)</p><p>In patients with chlamydia who are not tested for gonorrhea, presumptive treatment for gonorrhea is warranted in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>In males with intracellular gram-negative diplococci on a Gram stain of urethral discharge, which has a high degree of sensitivity and specificity for gonococci. (See  <a class="medical medical_review" href="/z/d/html/86698.html" rel="external">"Urethritis in adult males", section on 'Gonococcal urethritis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of gonococcal infection is high, either because of high individual risk (eg, partner with new diagnosis of gonorrhea) or because of high local prevalence rates of gonorrhea (eg, greater than 5 percent) [<a href="#rid9">9</a>]. This type of information is obtained by calling the local public health department or checking surveillance information on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLHq8mbzWsgxDyB8T08QViwGvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=7579" target="_blank">CDC website</a>. </p><p></p><p>Presumptive treatment of gonorrhea coinfection in all patients with chlamydia is not routinely warranted because the prevalence of gonorrhea in patients with chlamydia is highly variable and often low. In certain high-risk populations, such as adolescents entering juvenile detention centers, coinfection rates as high as 50 percent have been documented [<a href="#rid29">29,30</a>]. However, in a study of more than 14,000 young adults aged 18 to 26 years in the general community, the overall prevalence of chlamydia was 4.1 percent, and the rate of concomitant gonococcal infection among those with chlamydia was 7.3 percent [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H254804062"><span class="h2">Screen for HIV and other STIs</span><span class="headingEndMark"> — </span>As infection with one sexually transmitted infection (STI) increases the risk of infection with others, individuals diagnosed with <em>C. trachomatis</em> infection should be tested for other STIs, including HIV, gonorrhea, and syphilis [<a href="#rid9">9</a>]. Screening for STIs is discussed in detail elsewhere  (<a class="graphic graphic_table graphicRef103391" href="/z/d/graphic/103391.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a> and  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p>Among individuals who do not have HIV, diagnosis of a bacterial STI, such as <em>C. trachomatis</em>, should trigger evaluation for pre-exposure prophylaxis candidacy. (See  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p class="headingAnchor" id="H2044781569"><span class="h2">Pregnancy testing</span><span class="headingEndMark"> — </span>Individuals of child-bearing potential with chlamydial infection should undergo pregnancy testing. This is particularly important if treatment with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is planned, as doxycycline is generally avoided during pregnancy.</p><p class="headingAnchor" id="H3347343228"><span class="h2">Counseling</span></p><p class="headingAnchor" id="H940881737"><span class="h3">Medication adherence</span><span class="headingEndMark"> — </span>It is important to educate the patient regarding treatment adherence, particularly if <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is prescribed. A test of cure is indicated if nonadherence is suspected. (See <a class="local">'Test of cure for select patients'</a> below.)</p><p>One study of males and females with uncomplicated genital chlamydial infection evaluated medication adherence to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> treatment by administering medications through an electronic medication system in which all pill box openings were electronically recorded [<a href="#rid32">32</a>]. Eighty percent of 223 patients returned their pill bottles for assessment. Patients were considered strictly adherent if they had opened their bottles for at least 12 of 14 doses; only 25 percent of the patients demonstrated this level of adherence.</p><p>The importance of medication adherence was illustrated by a study in which imperfect adherence to a week-long course of oral <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, defined as missing one or more doses, conferred a ninefold risk of microbiologic failure among males with urethritis due to <em>C. trachomatis </em>[<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H4000135055"><span class="h3">Sexual activity</span><span class="headingEndMark"> — </span>To avoid reinfection, patients should be instructed to abstain from sexual intercourse until they and their sex partners have been adequately treated (ie, after completion of a seven-day regimen or for seven days after a single-dose regimen) and any symptoms have resolved. </p><p class="headingAnchor" id="H2688704938"><span class="h2">Follow-up testing</span><span class="headingEndMark"> — </span>There are two different strategies for testing for chlamydia after treatment, retesting and test of cure. </p><p class="headingAnchor" id="H40643231"><span class="h3">Retesting for all patients</span><span class="headingEndMark"> — </span>We agree with CDC recommendations to retest all patients with documented chlamydial infection for <em>C. trachomatis</em> three months after treatment (or at first opportunity prior to standard annual screening). The primary purpose of retesting is to detect reinfection with <em>C. trachomatis</em>. Retesting should be performed regardless of whether sex partners were treated and even if a test of cure four weeks after treatment completion was negative. </p><p>Epidemiologic studies have documented that persons with chlamydial infection often have a history of recently treated infection in the preceding months [<a href="#rid34">34,35</a>]. A systematic review of 38 studies of females with <em>C. trachomatis</em> reported a median reinfection rate of 14 percent (range 0 to 32 percent); higher rates were associated with younger age [<a href="#rid36">36</a>]. Similarly, in a study of over 144,000 positive chlamydia tests performed at a single large laboratory in the United States, the rates of repeat positive tests were 16, 14, and 15 percent among males and nonpregnant and pregnant females, respectively [<a href="#rid37">37</a>]. Repeat infections confer an increased risk of developing complicated genital infections, such as PID. Retesting is particularly important in the pregnant woman since recurrent infection could put the infant at risk of <em>C. trachomatis</em> ocular infection at birth [<a href="#rid9">9</a>].</p><p>Most recurrent chlamydial infections result from resumption of unprotected sex with an untreated sex partner; a history that all partners were treated is often unreliable. Some recurrent infections are acquired from new partners. </p><p class="headingAnchor" id="H1578861055"><span class="h3">Test of cure for select patients</span><span class="headingEndMark"> — </span>"Test of cure" means diagnostic testing to assess whether the administered antibiotic regimen eradicated the pathogen. Test of cure is not routinely warranted. We suggest test of cure in the following situations, when there is a risk of suboptimal microbiologic cure rates: </p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy, regardless of treatment administered</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent symptoms </p><p class="bulletIndent1"><span class="glyph">●</span>Concern for nonadherence to the regimen</p><p class="bulletIndent1"><span class="glyph">●</span>Use of a regimen with inferior cure rates, such as <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> or <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> treatment of patients with or at high risk for rectal infection </p><p></p><p>In these situations, test of cure should be performed no sooner than four weeks after treatment is completed. This is especially important when NAATs are used because <em>C. trachomatis</em> nucleic acid may still be detectable several weeks after treatment despite an absence of viable organisms [<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H2768564091"><span class="h2">Management of sex partners</span><span class="headingEndMark"> — </span>Infected sex partners are often asymptomatic and, unless treated, can reinfect the index patient or transmit infection to other partners. In fact, rates of reinfection among index cases of females with <em>C. trachomatis</em> range from 15 to 30 percent and are typically associated with resumption of sex with previously established partners [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H3226625964"><span class="h3">Partner assessment and treatment</span><span class="headingEndMark"> — </span>Ideally, sex partners of individuals with <em>C. trachomatis</em> infection should be examined, tested for <em>C. trachomatis</em> and <em>N. gonorrhoeae</em>, presumptively treated for <em>C. trachomatis</em>, and counseled on prevention. This should occur for all individuals who had sexual contact with the patient within the 60 days prior to infection or the most recent sex partner if the last contact was more than 60 days prior. </p><p>Using public health field workers to notify exposed sex partners to have them present to medical attention or be evaluated and treated in the field is costly and not available in most areas. With few exceptions, patients and their health care providers must assume responsibility for partner management. In such cases, expedited partner therapy (EPT) is a potential recourse, as discussed below.</p><p class="headingAnchor" id="H2136213054"><span class="h3">Expedited partner therapy</span><span class="headingEndMark"> — </span>A strategy termed "expedited partner therapy" (EPT) is a way to increase the proportion of sex partners receiving treatment and to decrease rates of reinfection in the index patient. EPT refers to facilitating treatment (without examination) by giving an antibiotic or a prescription to the index patient so they can provide it to their partners or by calling in a prescription directly for the partner [<a href="#rid41">41</a>]. We suggest EPT when it is uncertain whether sex partners of individuals with <em>C. trachomatis</em> infection will attend a clinical facility for evaluation and treatment. However, for men who have sex with men (MSM), the decision to use EPT should be weighed against the potential missed opportunities to evaluate and counsel partners around other potential coinfections, including HIV [<a href="#rid9">9</a>]. In the United States, EPT is not prohibited in any state [<a href="#rid42">42</a>]. </p><p>Regimen selection for EPT is the same as for treatment of chlamydia in general, which is discussed elsewhere (see <a class="local">'Antibiotic regimens in adults and adolescents'</a> above). EPT regimens for partners who warrant therapy for gonorrhea as well (eg, because of documented or presumptive infection in the index individual) are also discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Management of sexual partners'</a>). Partners should also be provided with information on the importance of treatment, symptoms of complications to watch for, and potential adverse effects of therapy. </p><p>Several trials have supported the role of EPT; however, these were conducted among heterosexual individuals. Data on EPT among MSM are limited. In a meta-analysis of five trials evaluating patient-delivered partner therapy, the risk of persistent or recurrent <em>C. trachomatis</em> or <em>N. gonorrhoeae</em> infection was lower compared with simple patient referral for partner management (summary risk ratio 0.73, 95% CI 0.57-0.93) [<a href="#rid43">43</a>]. One of the included trials had randomly assigned 2751 patients (23 percent male) with diagnosed <em>C. trachomatis</em> infection, <em>N. gonorrhoeae</em> infection, or both to either an "expedited treatment group" or a standard referral group [<a href="#rid44">44</a>]. Patients in the expedited treatment group were given packets of <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a> and/or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> to distribute to their partners, without requiring a formal medical evaluation of the partners. In the standard referral arm, patients simply notified their sex partners of the need for evaluation and treatment. Patients assigned to expedited treatment of sex partners were significantly more likely to report that all of their partners had been treated compared with those assigned to the standard referral arm (61 versus 49 percent). The trial also demonstrated a reduction in recurrent infections among those assigned to expedited treatment (relative risk of reinfection 0.75, 95% CI 0.56 to 0.97) [<a href="#rid45">45</a>].</p><p>The limitations of EPT include lost opportunities for screening and counseling [<a href="#rid46">46</a>] and a risk of adverse events related to antibiotic administration. Implementation research has also indicated that prescription EPT (in which patients are given prescriptions to provide to their partners) has more barriers to partner treatment than patient-delivered antibiotic [<a href="#rid47">47</a>]. Individual health care institutions also may have policies or regulations that preclude treatment of persons not enrolled in the institution. In the United States, however, the CDC consensus is that EPT offers a valuable means to control STIs and is an option for partner management, although ongoing evaluation of this approach is needed [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H22"><span class="h1">CONSIDERATIONS FOR EXTRAGENITAL INFECTIONS</span></p><p class="headingAnchor" id="H23"><span class="h2">Proctitis and rectal infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proctitis </strong>– Empiric therapy for both chlamydia and gonorrhea is indicated for the treatment of patients with sexually acquired proctitis. An empiric regimen of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily) plus a single intramuscular dose of <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (500 mg [or 1 g for individuals ≥150 kg]) is active against both [<a href="#rid9">9,48</a>]. The duration of doxycycline therapy depends on the severity of symptoms. Patients with severe proctitis may have lymphogranuloma venereum infection (LGV), which requires a full three-week course of doxycycline [<a href="#rid49">49</a>]. For patients with mild proctitis, seven days of therapy are likely adequate; however, some clinicians reasonably opt to treat these patients with the three-week course recommended for presumed LGV, particularly if nucleic acid amplification testing (NAAT) for <em>C. trachomatis</em> is positive. The clinical features of chlamydial proctitis and suspected LGV are discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/7593.html" rel="external">"Lymphogranuloma venereum"</a> and  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections", section on 'Proctitis and rectal infection'</a>). Consideration of other potential pathogens in proctitis among men who have sex with men (MSM) is also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3730.html" rel="external">"Evaluation of anorectal symptoms in men who have sex with men", section on 'Proctitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic rectal infection</strong> – Individuals who have isolated <em>C. trachomatis</em> infection of the rectum detected on screening (ie, positive <em>C. trachomatis</em> NAAT with negative <em>N. gonorrhoeae</em> NAAT) can be treated with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily) alone for one week. </p><p></p><p>We strongly favor <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> over <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> as the anti-chlamydial agent for acute proctitis and rectal infection because evidence indicates it eradicates infection considerably more effectively, although data on clinical cure for symptomatic infection are sparse. </p><p>Among males, two randomized, placebo-controlled trials of MSM who had a positive <em>C. trachomatis</em> NAAT on rectal screening demonstrated higher microbiologic cure rates at four weeks with one week of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> than with single-dose <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (in one trial of 177 participants: 91 versus 71 percent, difference 20 percent, 95% CI 9-31; and in another trial of 587 participants: 97 versus 76 percent, adjusted difference 20 percent, 95% CI 16-25) [<a href="#rid50">50,51</a>]. Almost all participants in both trials reported adherence to the seven-day course of doxycycline or placebo. </p><p>Among females, a randomized open-label trial of 357 participants with concurrent vaginal and anorectal <em>C. trachomatis</em> infection also demonstrated higher microbiologic cure rates at six weeks with one week of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> than with single-dose <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (94 versus 85 percent, adjusted difference 9 percent, 95% CI 6-13) [<a href="#rid52">52</a>]. </p><p>Observational studies in males and females have similarly suggested that <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is associated with higher microbiologic cure rates [<a href="#rid53">53,54</a>]. Pharmacokinetic and animal studies also suggest that <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> may not be optimal for rectal infection [<a href="#rid55">55,56</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Epididymitis</span><span class="headingEndMark"> — </span><em>N. gonorrhoeae</em> and <em>C. trachomatis</em> are the most frequent laboratory-identified pathogens causing epididymitis among sexually active males &lt;35 years of age. Empiric treatment of acute epididymitis covers these organisms [<a href="#rid57">57</a>]. Management of patients with acute epididymitis is discussed elsewhere.</p><p>We recommend the combination of <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (500 mg [or 1 g for individuals ≥150 kg]) as a single dose plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily) for 10 days for the treatment of sexually transmitted acute epididymitis [<a href="#rid9">9,48</a>]. There are no data on the use of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> for chlamydia in patients with epididymitis. Azithromycin can be an alternative for patients with a history of intolerance/allergy to doxycycline, but follow-up to evaluate for symptom resolution should be conducted.</p><p><a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> (500 mg daily for 10 days) is given instead of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) to patients with epididymitis who practice insertive anal sex (because of the possible involvement with enteric organisms) and can also be used for patients who are allergic to tetracyclines; levofloxacin is also active against chlamydia. (See <a class="local">'Alternative antibiotics'</a> above.)</p><p class="headingAnchor" id="H5623758"><span class="h2">Pelvic inflammatory disease</span><span class="headingEndMark"> — </span>When cervical infection is untreated, <em>C. trachomatis</em> ascends to the upper genital tract at least 20 percent of the time, which may manifest as either silent infection ("subclinical" pelvic inflammatory disease [PID] or silent endometritis) or overt PID [<a href="#rid58">58,59</a>]. Therefore, females with cervicitis should undergo a physical examination to exclude signs of upper tract disease (eg, cervical motion, uterine, or adnexal tenderness). Apart from direct involvement of the pelvic organs, PID can also include peritonitis and inflammation of the liver capsule (Fitzhugh-Curtis syndrome). Treatment for PID should provide broad coverage for the wide array of implicated pathogens, including antibiotics active against <em>C. trachomatis</em>, most commonly <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. The management of PID is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H5623402"><span class="h2">Oropharyngeal infection</span><span class="headingEndMark"> — </span>The clinical significance of oropharyngeal chlamydia is uncertain. Some studies have suggested the feasibility of transmission from oropharyngeal to genital sites [<a href="#rid60">60,61</a>]. However, a subsequent study suggested that the incidence and duration of pharyngeal chlamydia were lower than those of other extragenital STIs [<a href="#rid62">62</a>]. The implications of these findings for population-level transmission are unclear. </p><p>Although the optimal treatment regimen for oropharyngeal chlamydia has not been well studied, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is the preferred option if <em>C. trachomatis</em> is detected from an oropharyngeal sample [<a href="#rid9">9</a>]. (See <a class="local">'Doxycycline as preferred agent'</a> above.)</p><p class="headingAnchor" id="H5624097"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H30"><span class="h2">Pregnant individuals</span></p><p class="headingAnchor" id="H182333755"><span class="h3">Antibiotic selection</span><span class="headingEndMark"> — </span>In addition to reducing the risk of complications of chlamydia in the mother, treatment of <em>C. trachomatis</em> during pregnancy prevents transmission to infants during passage through the birth canal, which can result in neonatal conjunctivitis or pneumonia. The recommended regimen for treatment of pregnant individuals is <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (1 g orally given as a single dose) [<a href="#rid9">9</a>]. <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">Amoxicillin</a> (500 mg orally three times daily for seven days) is an alternative for those who cannot use azithromycin. </p><p>Macrolides (eg, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>) are commonly used during pregnancy. Although first-trimester use of macrolides (primarily <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> administered for several days) was associated with an increased risk of congenital malformations compared with penicillins in one large study, the risk associated with a single dose of azithromycin remains unknown [<a href="#rid63">63</a>]. We feel that the benefits of azithromycin in this situation outweigh the possible risk. The efficacy of azithromycin is discussed elsewhere. (See <a class="local">'Antibiotic regimens in adults and adolescents'</a> above.)</p><p><a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">Amoxicillin</a> is an alternative because in vitro studies raised concern that penicillins could induce a persistent state that allowed re-emergence of viable pathogen after discontinuation [<a href="#rid8">8</a>]. Although a short course of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> may be safe during pregnancy, it is generally avoided when other alternatives are available. <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> estolate are contraindicated in pregnancy and lactation.</p><p>Individuals who present in labor with an untreated prior positive <em>C. trachomatis</em> screening test should be treated immediately. However, this may not substantially decrease the risk of transmission of chlamydia to the newborn. (See  <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn", section on 'Risk of transmission'</a> and  <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H5348136"><span class="h3">Follow-up</span><span class="headingEndMark"> — </span>Follow-up of pregnant women treated for documented <em>C. trachomatis</em> infection includes both test of cure and repeat testing for reinfection. </p><p>Cure rates of <em>C. trachomatis</em> in pregnant females are generally lower than in nonpregnant females [<a href="#rid64">64</a>], particularly with the alternative agent <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>. For this reason, a test of cure is recommended for all pregnant women and should be performed no earlier than four weeks after treatment is completed. (See <a class="local">'Test of cure for select patients'</a> above.)</p><p>As with all patients with documented <em>C. trachomatis</em> infection, pregnant individuals should undergo repeat testing to evaluate for reinfection three months following treatment. (See <a class="local">'Retesting for all patients'</a> above.) </p><p class="headingAnchor" id="H31"><span class="h2">Patients with HIV</span><span class="headingEndMark"> — </span>The treatment of patients with HIV and <em>C. trachomatis</em> infections is the same as in patients without HIV.</p><p class="headingAnchor" id="H1759938394"><span class="h2">Children</span><span class="headingEndMark"> — </span>The optimal treatment approach for <em>C. trachomatis</em> infection in children is uncertain. Treatment of neonatal <em>C. trachomatis</em> infection is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn", section on 'Treatment'</a>.)</p><p>For other infants and children, we agree with the following regimens recommended by the CDC in the United States [<a href="#rid9">9</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children &lt;45 kg</strong> – <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">Erythromycin</a> base or ethylsuccinate 50 mg/kg per day, divided into four daily doses for 14 days. Data on optimal use and dosing of other anti-chlamydial agents for children of this size are lacking. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children ≥45 kg</strong> – <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> 1 g orally in a single dose.</p><p></p><p class="bulletIndent1">Another option for children ≥45 kg and ≥8 years old is <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg orally twice daily for seven days.</p><p></p><p>The CDC recommends test of cure for children at least four weeks after therapy [<a href="#rid9">9</a>]. </p><p>The possibility of sexual abuse should be assessed in children diagnosed with chlamydia, although perinatally acquired infection can persist for several years. (See  <a class="medical medical_review" href="/z/d/html/6605.html" rel="external">"Evaluation of sexual abuse in children and adolescents", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H342755"><span class="h1">PERSISTENT OR RECURRENT SYMPTOMS</span></p><p class="headingAnchor" id="H1131209258"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>It is important that patients treated for chlamydia be counseled to monitor for symptom resolution and return for evaluation of persistent or recurrent symptoms. Such symptoms could reflect incomplete adherence to the therapeutic regimen, reinfection, or infection with another pathogen not optimally treated with the initial antibiotic regimen. </p><p>For patients with persistent or recurrent symptoms, clinicians should evaluate for possible reinfection, including inquiring about whether sex partners were treated, and for other sexually transmitted infections (STIs). Other etiologic agents to consider include <em>Mycoplasma genitalium</em>, <em>Trichomonas vaginalis</em>, and genital herpes.</p><p>Evaluation and empiric management of recurrent urethritis, cervicitis, and other syndromes associated with <em>C. trachomatis</em> are discussed in detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86698.html" rel="external">"Urethritis in adult males", section on 'Recurrent or persistent symptoms'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5460.html" rel="external">"Acute cervicitis", section on 'Recurrent or persistent disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents", section on 'Follow-up'</a>.)</p><p></p><p></p><p>Persistent symptoms after appropriate therapy with good adherence are usually not due to primary treatment failure, as suggested by studies that evaluated the likelihood of the organism persisting after appropriate antibiotic therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>In a detailed prospective evaluation of 20 females with culture-proven and polymerase chain reaction (PCR)-proven <em>C. trachomatis</em> urogenital infections treated with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, no evidence of persistent infection was detected after five months of serial sampling with PCR, culture, and serial measurements of local and systemic antibody to <em>C. trachomatis </em>[<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One longitudinal prospective study of adolescent females with chlamydia used DNA genotyping and behavioral histories to assess whether repeated chlamydial infections may be related to reinfection versus treatment failure with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid66">66</a>]. Of 183 repeat infections, only 25 (14 percent) were classified as probable or possible treatment failures. </p><p></p><p class="headingAnchor" id="H342789"><span class="h2">Management of repeat infection</span><span class="headingEndMark"> — </span>If <em>C. trachomatis</em> is again detected on repeat testing for persistent or recurrent symptoms or on routine repeat testing, we treat with the same regimen recommended for initial therapy. (See <a class="local">'Doxycycline as preferred agent'</a> above.)</p><p>Persistence or recurrence of symptoms should not be attributed to <em>C. trachomatis</em> drug resistance [<a href="#rid67">67</a>]; drug resistance to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>) has not been demonstrated to date.</p><p>Although the swine pathogen, <em>Chlamydia suis</em>, is commonly <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> resistant, there are no examples of stable tetracycline resistance in clinical strains of <em>C. trachomatis</em>. One in vitro study was able to demonstrate that a clinical strain of <em>C. trachomatis</em> was able to acquire a resistance element from a <em>C. suis</em> strain within coculture experiments [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H48"><span class="h1">SCREENING FOR CHLAMYDIA</span><span class="headingEndMark"> — </span>Screening for <em>C. trachomatis</em> is a critically important tool in the control of this infection and is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Chlamydia and gonorrhea'</a>.)</p><p class="headingAnchor" id="H455690371"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H30580089"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15379.html" rel="external">"Patient education: Chlamydia and gonorrhea (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4015.html" rel="external">"Patient education: Chlamydia (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H49"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment</strong> – These are to prevent complicated infections related to chlamydia (eg, pelvic inflammatory disease [PID], infertility, ectopic pregnancy), decrease the risk of transmission to others, resolve symptoms in those who have them, and prevent reinfection. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial susceptibility </strong>– Agents with excellent activity against <em>Chlamydia trachomatis</em> include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (a tetracycline) and <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (a macrolide). Certain fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>) also have good activity but are infrequently used. Penicillins are associated with persistence of <em>C. trachomatis</em> in vitro, and cephalosporins and sulfonamides have limited activity. (See <a class="local">'Antimicrobial susceptibility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Doxycycline</strong><strong> preferred in nonpregnant individuals </strong>– For nonpregnant individuals with <em>C. trachomatis</em> infection, we suggest <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> rather than <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Although clinical cure rates are comparable, microbial cure rates with azithromycin are lower compared with doxycycline, particularly for rectal infection and genital infection in males; this has potential important public health consequences and, in females, might increase the risk of repeat genital infection from an inadequately treated rectal infection. Doxycycline dosing and alternative agents are listed in the table  (<a class="graphic graphic_table graphicRef141567" href="/z/d/graphic/141567.html" rel="external">table 1</a>). (See <a class="local">'Doxycycline as preferred agent'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azithromycin</strong><strong> preferred in pregnancy </strong>– For pregnant individuals with <em>C. trachomatis</em> infection, we suggest <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Although a short course of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> may be safe during pregnancy, it is generally avoided when effective alternatives are available because of uncertain risk. Dosing is listed in the table  (<a class="graphic graphic_table graphicRef141567" href="/z/d/graphic/141567.html" rel="external">table 1</a>). (See <a class="local">'Pregnant individuals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test for and treat other STIs </strong>– All patients with <em>C. trachomatis</em> infection should be tested for <em>Neisseria gonorrhoeae</em> and treated if positive  (<a class="graphic graphic_table graphicRef141567" href="/z/d/graphic/141567.html" rel="external">table 1</a>); they should also be screened for other sexually transmitted infections (STIs), including HIV  (<a class="graphic graphic_table graphicRef103391" href="/z/d/graphic/103391.html" rel="external">table 2</a>). (See <a class="local">'Evaluate for and treat gonococcal coinfection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling on sexual activity</strong> – Individuals should refrain from sexual activity until they have completed the seven-day treatment regimen (or seven days have elapsed after single-dose treatment), any symptoms have resolved, and sex partners have been treated. (See <a class="local">'Sexual activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of sex partners</strong> – Treatment of sex partners is essential for preventing reinfection and controlling the spread of infection. The following sex partners of the patient should be treated for <em>C. trachomatis</em>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any sex partner within 60 days of infection</p><p class="bulletIndent2"><span class="glyph">•</span>The most recent sex partner if &gt;60 days from infection</p><p></p><p class="bulletIndent1">If sex partners of persons wi<em>th C. trachomatis</em> infection are unlikely to present for evaluation and treatment, we suggest expedited partner therapy (EPT) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This entails providing the index patient with a prescription so they can pass it to their partner or calling it in directly to the partner. For men who have sex with men (MSM), the decision to use EPT should be weighed against the potential missed opportunities to evaluate and counsel partners around other potential coinfections, including HIV. (See <a class="local">'Management of sex partners'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up testing:</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Test of cure at four weeks after treatment is warranted for pregnant individuals, persistent symptoms, and concern for nonadherence to the treatment regimen. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All individuals treated for <em>C. trachomatis</em> infection should undergo retesting after three months to identify reinfection. (See <a class="local">'Follow-up testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent infection</strong> – This is most likely due to reinfection and is treated with the same approach as for initial infection. Drug resistance to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, or fluoroquinolones has not been described. (See <a class="local">'Management of repeat infection'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Stamm WE. Chlamydia trachomatis infections of the adult. In: Sexually Transmitted Diseases, 4th Edition, Holmes KK, Sparling PF, Mardh PA, et al (Eds), McGraw-Hill, New York 2008. p.575.</li><li><a class="nounderline abstract_t">Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362.</a></li><li><a class="nounderline abstract_t">Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010; 340:c1642.</a></li><li><a class="nounderline abstract_t">Ostergaard L, Andersen B, Møller JK, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis 2000; 31:951.</a></li><li><a class="nounderline abstract_t">Hillis SD, Joesoef R, Marchbanks PA, et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168:1503.</a></li><li><a class="nounderline abstract_t">Thorpe EM Jr, Stamm WE, Hook EW 3rd, et al. Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises. Genitourin Med 1996; 72:93.</a></li><li><a class="nounderline abstract_t">Geisler WM. Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2015; 61 Suppl 8:S774.</a></li><li><a class="nounderline abstract_t">Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 2010; 201 Suppl 2:S88.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis 2012; 55:82.</a></li><li><a class="nounderline abstract_t">Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis 2011; 52:163.</a></li><li><a class="nounderline abstract_t">Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis 2013; 56:934.</a></li><li><a class="nounderline abstract_t">Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 59:193.</a></li><li><a class="nounderline abstract_t">Kissinger PJ, White S, Manhart LE, et al. Azithromycin Treatment Failure for Chlamydia trachomatis Among Heterosexual Men With Nongonococcal Urethritis. Sex Transm Dis 2016; 43:599.</a></li><li><a class="nounderline abstract_t">Páez-Canro C, Alzate JP, González LM, et al. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev 2019; 1:CD010871.</a></li><li><a class="nounderline abstract_t">Geisler WM, Uniyal A, Lee JY, et al. Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection. N Engl J Med 2015; 373:2512.</a></li><li><a class="nounderline abstract_t">Manavi K, Hettiarachchi N, Hodson J. Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection. Int J STD AIDS 2016; 27:1303.</a></li><li><a class="nounderline abstract_t">Chandra NL, Broad C, Folkard K, et al. Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis. Sex Transm Infect 2018; 94:320.</a></li><li><a class="nounderline abstract_t">Rank RG, Yeruva L. An alternative scenario to explain rectal positivity in Chlamydia-infected individuals. Clin Infect Dis 2015; 60:1585.</a></li><li><a class="nounderline abstract_t">Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29:497.</a></li><li><a class="nounderline abstract_t">Foglia G, Rhodes P, Goldberg M, St Louis ME. Completeness of and duration of time before treatment after screening women for Chlamydia trachomatis infections. Sex Transm Dis 1999; 26:421.</a></li><li><a class="nounderline abstract_t">McNulty CA, Boyle P, Nichols T, et al. The public's attitudes to and compliance with antibiotics. J Antimicrob Chemother 2007; 60 Suppl 1:i63.</a></li><li><a class="nounderline abstract_t">Bachmann LH, Stephens J, Richey CM, Hook EW 3rd. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999; 26:272.</a></li><li><a class="nounderline abstract_t">Mogabgab WJ, Holmes B, Murray M, et al. Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. Chemotherapy 1990; 36:70.</a></li><li><a class="nounderline abstract_t">Hooton TM, Batteiger BE, Judson FN, et al. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36:1144.</a></li><li><a class="nounderline abstract_t">McCormack WM, Martin DH, Hook EW 3rd, Jones RB. Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection. Infect Dis Obstet Gynecol 1998; 6:109.</a></li><li><a class="nounderline abstract_t">Hooton TM, Rogers ME, Medina TG, et al. Ciprofloxacin compared with doxycycline for nongonococcal urethritis. Ineffectiveness against Chlamydia trachomatis due to relapsing infection. JAMA 1990; 264:1418.</a></li><li><a class="nounderline abstract_t">Geisler WM. Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007; 44 Suppl 3:S77.</a></li><li><a class="nounderline abstract_t">Kahn RH, Mosure DJ, Blank S, et al. Chlamydia trachomatis and Neisseria gonorrhoeae prevalence and coinfection in adolescents entering selected US juvenile detention centers, 1997-2002. Sex Transm Dis 2005; 32:255.</a></li><li><a class="nounderline abstract_t">Nsuami M, Cammarata CL, Brooks BN, et al. Chlamydia and gonorrhea co-occurrence in a high school population. Sex Transm Dis 2004; 31:424.</a></li><li><a class="nounderline abstract_t">Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229.</a></li><li><a class="nounderline abstract_t">Augenbraun M, Bachmann L, Wallace T, et al. Compliance with doxycycline therapy in sexually transmitted diseases clinics. Sex Transm Dis 1998; 25:1.</a></li><li><a class="nounderline abstract_t">Khosropour CM, Manhart LE, Colombara DV, et al. Suboptimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect 2014; 90:3.</a></li><li><a class="nounderline abstract_t">Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001; 28:117.</a></li><li><a class="nounderline abstract_t">Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007; 83:304.</a></li><li><a class="nounderline abstract_t">Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009; 36:478.</a></li><li><a class="nounderline abstract_t">Hoover KW, Tao G, Nye MB, Body BA. Suboptimal adherence to repeat testing recommendations for men and women with positive Chlamydia tests in the United States, 2008-2010. Clin Infect Dis 2013; 56:51.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep 2014; 63:1.</a></li><li><a class="nounderline abstract_t">Renault CA, Israelski DM, Levy V, et al. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health 2011; 8:69.</a></li><li><a class="nounderline abstract_t">Gaydos CA, Wright C, Wood BJ, et al. Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers. Sex Transm Dis 2008; 35:233.</a></li><li><a class="nounderline abstract_t">Hogben M. Partner notification for sexually transmitted diseases. Clin Infect Dis 2007; 44 Suppl 3:S160.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Expedited partner therapy. https://www.cdc.gov/std/ept/ (Accessed on October 21, 2021).</li><li><a class="nounderline abstract_t">Trelle S, Shang A, Nartey L, et al. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ 2007; 334:354.</a></li><li><a class="nounderline abstract_t">Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Expedited Partner Therapy in the Management of Sexually Transmitted Diseases: Review and guidance. https://www.cdc.gov/std/treatment/eptfinalreport2006.pdf (Accessed on October 21, 2021).</li><li><a class="nounderline abstract_t">Khan A, Fortenberry JD, Juliar BE, et al. The prevalence of chlamydia, gonorrhea, and trichomonas in sexual partnerships: implications for partner notification and treatment. Sex Transm Dis 2005; 32:260.</a></li><li><a class="nounderline abstract_t">Kissinger PJ. The Challenges of Implementing and Evaluating Prescription Expedited Partner Treatment. Sex Transm Dis 2017; 44:109.</a></li><li><a class="nounderline abstract_t">St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1911.</a></li><li><a class="nounderline abstract_t">Leeyaphan C, Ong JJ, Chow EP, et al. Systematic Review and Meta-Analysis of Doxycycline Efficacy for Rectal Lymphogranuloma Venereum in Men Who Have Sex with Men. Emerg Infect Dis 2016; 22:1778.</a></li><li><a class="nounderline abstract_t">Dombrowski JC, Wierzbicki MR, Newman LM, et al. Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial. Clin Infect Dis 2021; 73:824.</a></li><li><a class="nounderline abstract_t">Lau A, Kong FYS, Fairley CK, et al. Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis. N Engl J Med 2021; 384:2418.</a></li><li><a class="nounderline abstract_t">Peuchant O, Lhomme E, Martinet P, et al. Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis 2022; 22:1221.</a></li><li><a class="nounderline abstract_t">Dukers-Muijrers NHTM, Wolffs PFG, De Vries H, et al. Treatment Effectiveness of Azithromycin and Doxycycline in Uncomplicated Rectal and Vaginal Chlamydia trachomatis Infections in Women: A Multicenter Observational Study (FemCure). Clin Infect Dis 2019; 69:1946.</a></li><li><a class="nounderline abstract_t">Kong FY, Tabrizi SN, Fairley CK, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother 2015; 70:1290.</a></li><li><a class="nounderline abstract_t">Rank RG, Yeruva L. Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infect Immun 2014; 82:1362.</a></li><li><a class="nounderline abstract_t">Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl A:73.</a></li><li class="breakAll">Geisler WM and Krieger JN. Epididymitis. In: Sexually Transmitted Diseases, 4, Holmes K, Sparling P, Stamm W, et al (Eds), McGraw Hill, 2008.</li><li><a class="nounderline abstract_t">Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456.</a></li><li><a class="nounderline abstract_t">Wiesenfeld HC, Sweet RL, Ness RB, et al. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005; 32:400.</a></li><li><a class="nounderline abstract_t">Marcus JL, Kohn RP, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra. Sex Transm Dis 2011; 38:372.</a></li><li><a class="nounderline abstract_t">Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis 2009; 49:1793.</a></li><li><a class="nounderline abstract_t">Khosropour CM, Soge OO, Golden MR, et al. Incidence and Duration of Pharyngeal Chlamydia Among a Cohort of Men Who Have Sex With Men. Clin Infect Dis 2022; 75:875.</a></li><li><a class="nounderline abstract_t">Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ 2020; 368:m331.</a></li><li><a class="nounderline abstract_t">Dionne-Odom J, Subramaniam A, Aaron KJ, et al. High rates of persistent and recurrent chlamydia in pregnant women after treatment with azithromycin. Am J Obstet Gynecol MFM 2020; 2:100216.</a></li><li><a class="nounderline abstract_t">Workowski KA, Lampe MF, Wong KG, et al. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection. JAMA 1993; 270:2071.</a></li><li><a class="nounderline abstract_t">Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010; 201:42.</a></li><li><a class="nounderline abstract_t">Suchland RJ, Dimond ZE, Putman TE, Rockey DD. Demonstration of Persistent Infections and Genome Stability by Whole-Genome Sequencing of Repeat-Positive, Same-Serovar Chlamydia trachomatis Collected From the Female Genital Tract. J Infect Dis 2017; 215:1657.</a></li><li><a class="nounderline abstract_t">Suchland RJ, Sandoz KM, Jeffrey BM, et al. Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. Antimicrob Agents Chemother 2009; 53:4604.</a></li></ol></div><div id="topicVersionRevision">Topic 7579 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Stamm WE. Chlamydia trachomatis infections of the adult. In: Sexually Transmitted Diseases, 4th Edition, Holmes KK, Sparling PF, Mardh PA, et al (Eds), McGraw-Hill, New York 2008. p.575.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8614421" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378636" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049776" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498436" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698374" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602617" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20470046" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chlamydia trachomatis persistence in vitro: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431798" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288838" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223595" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24729507" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27631353" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Azithromycin Treatment Failure for Chlamydia trachomatis Among Heterosexual Men With Nongonococcal Urethritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30682211" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26699167" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26511655" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29431148" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25648236" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : An alternative scenario to explain rectal positivity in Chlamydia-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218839" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10494931" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Completeness of and duration of time before treatment after screening women for Chlamydia trachomatis infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656386" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The public's attitudes to and compliance with antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333280" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2307026" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1510408" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9785106" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2391738" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ciprofloxacin compared with doxycycline for nongonococcal urethritis. Ineffectiveness against Chlamydia trachomatis due to relapsing infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342671" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15788927" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Chlamydia trachomatis and Neisseria gonorrhoeae prevalence and coinfection in adolescents entering selected US juvenile detention centers, 1997-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215698" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chlamydia and gonorrhea co-occurrence in a high school population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138245" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence of chlamydial and gonococcal infections among young adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9437776" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Compliance with doxycycline therapy in sexually transmitted diseases clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24106340" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Suboptimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234786" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166889" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19617871" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23074316" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Suboptimal adherence to repeat testing recommendations for men and women with positive Chlamydia tests in the United States, 2008-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24622331" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371385" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490866" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342669" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Partner notification for sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342669" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Partner notification for sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17237298" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716561" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716561" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15788928" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The prevalence of chlamydia, gonorrhea, and trichomonas in sexual partnerships: implications for partner notification and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28081047" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The Challenges of Implementing and Evaluating Prescription Expedited Partner Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332296" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27513890" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Systematic Review and Meta-Analysis of Doxycycline Efficacy for Rectal Lymphogranuloma Venereum in Men Who Have Sex with Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33606009" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34161706" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35550262" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30689759" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment Effectiveness of Azithromycin and Doxycycline in Uncomplicated Rectal and Vaginal Chlamydia trachomatis Infections in Women: A Multicenter Observational Study (FemCure).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637520" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24421044" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2154441" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The pharmacokinetics of azithromycin in human serum and tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2154441" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The pharmacokinetics of azithromycin in human serum and tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220764" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976596" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of acute and subclinical pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21183864" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911970" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34893806" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Incidence and Duration of Pharyngeal Chlamydia Among a Cohort of Men Who Have Sex With Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32075790" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33345925" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : High rates of persistent and recurrent chlamydia in pregnant women after treatment with azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8305018" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19929379" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Repeated Chlamydia trachomatis genital infections in adolescent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28368459" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Demonstration of Persistent Infections and Genome Stability by Whole-Genome Sequencing of Repeat-Positive, Same-Serovar Chlamydia trachomatis Collected From the Female Genital Tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687238" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
